|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||108.20 - 109.00|
|52-week range||104.50 - 143.90|
|Beta (5Y monthly)||0.10|
|PE ratio (TTM)||35.72|
|Forward dividend & yield||2.81 (2.14%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
AZN vs. LLY: Which Stock Is the Better Value Option?
You don't need a mountain of cash to build wealth on Wall Street -- especially with deals like these.
AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.